ADAP

Adaptimmune Therapeutics
ADAP

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

49 hedge funds and large institutions have $103M invested in Adaptimmune Therapeutics in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

less ownership

Funds ownership: →

less repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

83% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 12

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
49
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$29K
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$576K
2
+$371K
3
+$318K
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$146K
5
Marshall Wace
Marshall Wace
United Kingdom
+$120K

Top Sellers

1
-$694K
2
-$611K
3
-$409K
4
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
-$355K
5
TCM
Tekla Capital Management
Massachusetts
-$228K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$39K
27
$34K
28
$33K
29
$32K
30
$30K
31
$29K
32
$27K
33
$4K
34
$3K
35
$3K
36
$3K
37
$2K
38
$1K
39
$1K
40
$1K
41
$1K
42
$1K
43
$183
44
–
45
–
46
–
47
–
48
–
49
–
50
–
1
2
3